I read the review Reflections on Errors in Neonatology III by Robertson 1 with great interest. Since the study of steroid use for the treatment of bronchopulmonary dysplasia (BPD), 2 in which I participated during my fellowship in Neonatology, was singled out, being the first randomized, controlled trial of its nature, I found this section of the review concerning steroid use for BPD of particular significance. However, Dr. Robertson's nonchalant dismissal of the steroid era, and his remarks on the apparent ease with which current-day neonatologists have managed to avoid using this therapy since it recently became taboo, do not reflect the conflicts and concerns about which we debated during that era. Let us rather step back in time and recall that BPD was frequently a devastating condition, and that there was a need, at the time we carried out this study, of finding a treatment, any treatment, for helping these unfortunate neonates and their families.
Any of us who were either practicing or training in neonatology at the time will recall that the respiratory outcome of small, premature neonates (not yet micropreemies) was quite different from what it is today. As pointed out by Dr. Robertson himself, nurseries were full of ventilator-dependent infants. Classic severe BPD, accompanied by roentgenographic changes of stages 3 and 4 BPD, infrequently encountered nowadays, were common occurrences. The clinical course was prolonged and complicated by suffering not only of the sick neonates, but of their families as well, to say nothing of the nursing and medical staff who had to care for these babies on a daily basis. To quote statistics drawn from a paper representative of that epoch, 21% of babies ventilated for respiratory distress syndrome developed radiographic stage IV BPD. 3 In total, 39% of these neonates died. The patients reported had a mean birth weight of 1.8 kg, and a mean gestational age of 33 weeks F a very different picture from what one would expect nowadays. We were prepared to try a new treatment modality that, albeit in an uncontrolled fashion, had shown signs of promise.
In contrast to subsequent studies in which steroids were used either prophylactically or very early, our study was intended for ventilator-dependent premature neonates with established BPD.
The protocol was planned in 1979 to 1980 and the study carried out in the early 1980s. The idea was based on uncontrolled work pioneered by Drs Kramer 4 and Hultzen of the Fairfax Hospital in Northern Virginia which seemed to reflect success in many treated prematures. Our aim was to prove, in a controlled, blinded fashion, that this therapeutic modality did indeed work. So life-threatening was the disease, and so encouraging were the preliminary results of the treatment, 4 that the research protocol allowed for crossover of control infants to the treatment modality once the acute stage of the study was over, so as not to deprive control neonates of the possible effect of therapy. However, there is no basis to Dr. Robertson's suggestion that the drug was administered with little concern as to its side effects. The complications and dangers of steroid therapy were most certainly kept in mind and closely monitored. Indeed, the paper concluded with a warning that risk versus benefit should be carefully balanced lest the cure be worse than the disease.
What did we look for, and what did we not study? We studied short-term (within 72 hours of administration of dexamethasone) improvement in lung function to promote weaning of respiratordependent babies with established BPD. It was not the aim of this study to determine long-term efficacy, nor long-standing safety. We did not demonstrate or claim to demonstrate decreased mortality or reduced hospital stay. What we did demonstrate was striking shortterm improvement in lung function, often sufficient to permit rapid weaning of the infants from the respirator.
During the 1980s and 1990s many ventilator-dependent BPD babies were treated, often successfully, with steroids. Encouragingly, several studies were performed subsequent to ours, some of which did look at long-term neurological outcome, but did not find increased neurological deficits in treated babies when compared with controls. 5, 6 The balance was upset in the late 1990s. Two studies 7, 8 randomized premature infants very early in life, before they had developed respirator dependency or chronic lung disease, to receive steroids in order to prevent these conditions. Increased neuromotor dysfunction and cerebral palsy were documented in the steroid-treated groups. Another study 9 demonstrated similar neurological findings, this time in ventilator-dependent prematures with established BPD. These babies, however, were considerably smaller and of lower gestational age than the babies we originally treated in the beginning of the previous decade. These studies suggested that the neurological complications of steroid use may have been enhanced by very young gestational age, or young postnatal age at the time of institution of therapy, and do not necessarily imply that the older, more mature baby with established, ventilator-dependent BPD would also develop the same neurological outcome as a result of steroid therapy. The subject has been comprehensively reviewed, and culminated in the recent recommendations of the American Academy of Pediatrics and the Canadian Pediatric Society not to use steroid therapy for this purpose routinely, except in exceptional circumstances and with parental understanding and permission, and if it is to be used, to do so within the framework of a controlled clinical trial. 10 Meanwhile, since the early 1980s, there have been other dramatic changes in prenatal and postnatal care administered to premature neonates. Prenatal steroid administration has become standard, surfactant therapy has become universally available, and ventilators are today capable of delivering gas and supporting ventilation much more gently, and with less barotrauma, than before. Many other neonatal intensive care monitoring, therapeutic and nutritional techniques have been refined. All these factors may be playing a major part in our ability in the 2000s to successfully manage the larger premature neonate without having to resort to steroids. The smaller, micropreemie nowadays encountered comprises the major challenge for the neonatologist. The recent studies imply that for this kind of baby, steroid therapy, especially when used prophylactically, may indeed be more harmful than helpful.
It is possible that some of the new therapeutic modalities may interact with postnatal steroid therapy to exacerbate its side effects. Antenatal steroids may cause an additive toxic effect. Possibly small, very immature neonates would benefit, without neurological damage, from short-term steroid use, rather than the arbitrary 6-week regimen we employed, or from low-dose steroid therapy. However, in light of the current recommendations, 10 it seems unlikely that such a study will be performed in the near future.
The use of steroid therapy must be viewed in light of the times in which it was used. Currently, its usefulness may be outweighed by modern advances in neonatal medicine. To brand this therapy a mistake, however, seems to belittle the benefits we were able to administer to our tiny charges at a time when little else, other than progressive chronic, respiratory disease, sometimes with a bleak or fatal outcome, was the only alternative.
Sincerely 
